Published on 29 Dec 2023 on Zacks via Yahoo Finance
Amicus (FOLD) Banks on Galafold, Overdependence a Concern
Amicus Therapeutics, Inc.’s FOLD lead drug, Galafold (migalastat), is the first and only approved oral medicine for patients living with Fabry disease, having amenable genetic variants. The drug has shown solid uptake since its launch.
Sales of Galafold have been rising consistently over the past years. In the first nine months of 2023, the drug generated sales worth $281.2 million, increasing 16.6% on a year-over-year basis. Galafold is currently approved in several countries, including the United States, European Union (EU), United Kingdom and Japan.
In 2021, Galafold received label expansion in the EU for long-term treatment of adolescents aged 12 years and older with Fabry disease. Such label expansion, along with approvals in additional geographies, is likely to drive sales of the drug further in 2024 and beyond.